Avidity Biosciences Inc (RNA)
28.72
-0.79
(-2.68%)
USD |
NASDAQ |
May 16, 16:00
29.61
+0.89
(+3.10%)
After-Hours: 20:00
Avidity Biosciences Cash from Operations (Quarterly): -70.38M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -70.38M |
| December 31, 2023 | 16.50M |
| September 30, 2023 | -36.79M |
| June 30, 2023 | -49.81M |
| March 31, 2023 | -48.97M |
| December 31, 2022 | -39.19M |
| September 30, 2022 | -31.96M |
| June 30, 2022 | -35.55M |
| March 31, 2022 | -29.57M |
| December 31, 2021 | -26.22M |
| September 30, 2021 | -20.78M |
| Date | Value |
|---|---|
| June 30, 2021 | -28.14M |
| March 31, 2021 | -19.68M |
| December 31, 2020 | -13.07M |
| September 30, 2020 | -9.113M |
| June 30, 2020 | -7.791M |
| March 31, 2020 | -7.14M |
| December 31, 2019 | -5.019M |
| September 30, 2019 | -5.885M |
| June 30, 2019 | 15.48M |
| March 31, 2019 | -2.086M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-70.38M
Minimum
Mar 2024
16.50M
Maximum
Dec 2023
-22.65M
Average
-23.50M
Median
Cash from Operations (Quarterly) Benchmarks
| Catalyst Pharmaceuticals Inc | 31.92M |
| Vertex Pharmaceuticals Inc | 1.307B |
| Codexis Inc | -7.789M |
| Sarepta Therapeutics Inc | -242.08M |
| PTC Therapeutics Inc | 70.76M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -32.75M |
| Cash from Financing (Quarterly) | 389.44M |
| Free Cash Flow | -143.80M |
| Free Cash Flow Per Share (Quarterly) | -0.8175 |
| Free Cash Flow to Equity (Quarterly) | -71.30M |
| Free Cash Flow Yield | -6.49% |